Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Bagel

Showing results (41-50 of 100) with videos related to

Pageof 10
Sort By:
Dermatology and Therapy|March 29, 2025
Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injectorMichael Sebastian, Jerry Bagel, Bengt Hoepken, et al.
JAMA Dermatology|December 18, 2014
Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis FoundationApril W Armstrong, Jerry Bagel, Abby S Van Voorhees, et al.
Journal of Drugs in Dermatology : JDD|December 5, 2013
Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasisLeon Kircik, Mark G Lebwohl, James Q Del Rosso, et al.
Journal of the American Academy of Dermatology|March 21, 2021
Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitisJoseph F Merola, Jerry Bagel, Peter Almgren, et al.
Journal of Drugs in Dermatology : JDD|August 19, 2016
The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST StudyCraig Leonardi, Jerry Bagel, Paul Yamauchi, et al.
Journal of Drugs in Dermatology : JDD|December 15, 2015
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST)Craig Leonardi, Jerry Bagel, Paul Yamauchi, et al.
Journal of Drugs in Dermatology : JDD|October 27, 2018
Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With ApremilastJerry Bagel, Ahmed S Samad, Bradley S Stolshek, et al.
The British Journal of Dermatology|May 29, 2026
Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded clinical trial to support interchangeabilityAndrew Blauvelt, Jerry Bagel, Andreas Pinter, et al.
The Journal of Dermatological Treatment|December 11, 2023
Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registryBruce Strober, Kristina Callis Duffin, Mark Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|February 21, 2018
Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEILLinda Stein Gold, Jerry Bagel, Mark Lebwohl, et al.
Pageof 10

Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
Dermatology and Therapy|March 29, 2025
Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injectorMichael Sebastian, Jerry Bagel, Bengt Hoepken, et al.
JAMA Dermatology|December 18, 2014
Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis FoundationApril W Armstrong, Jerry Bagel, Abby S Van Voorhees, et al.
Journal of Drugs in Dermatology : JDD|December 5, 2013
Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasisLeon Kircik, Mark G Lebwohl, James Q Del Rosso, et al.
Journal of the American Academy of Dermatology|March 21, 2021
Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitisJoseph F Merola, Jerry Bagel, Peter Almgren, et al.
Journal of Drugs in Dermatology : JDD|August 19, 2016
The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST StudyCraig Leonardi, Jerry Bagel, Paul Yamauchi, et al.
Journal of Drugs in Dermatology : JDD|December 15, 2015
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST)Craig Leonardi, Jerry Bagel, Paul Yamauchi, et al.
Journal of Drugs in Dermatology : JDD|October 27, 2018
Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With ApremilastJerry Bagel, Ahmed S Samad, Bradley S Stolshek, et al.
The British Journal of Dermatology|May 29, 2026
Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded clinical trial to support interchangeabilityAndrew Blauvelt, Jerry Bagel, Andreas Pinter, et al.
The Journal of Dermatological Treatment|December 11, 2023
Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registryBruce Strober, Kristina Callis Duffin, Mark Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|February 21, 2018
Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEILLinda Stein Gold, Jerry Bagel, Mark Lebwohl, et al.
Pageof 10